CASI Pharma (NASDAQ:CASI) target price raised to $4.00, reported today by Maxim Group
- Updated: September 21, 2016
CASI Pharma (NASDAQ:CASI) had its price target upped to $4.00 by Maxim Group in an issued report announced 09/22/2016. The bumped up target price indicates a possible upside of 2.81% based on the company's last closing price.
Previously on 6/23/2015, H.C. Wainwright reported on CASI Pharma (NASDAQ:CASI) increased the target price from $0.00 to $2.00. At the time, this indicated a possible upside of 0.20%.
Yesterday CASI Pharma (NASDAQ:CASI) traded -1.87% lower at $1.05. The company’s 50-day moving average is $1.11 and its 200-day moving average is $1.18. The last closing price is down -10.79% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time period. 2,168 shares of the stock traded hands, down from an average trading volume of 48,664
See Chart Below
CASI Pharma has a with a one year low of $0.58 and a one year high of $1.82 CASI’s total market value is presently $0.
More About CASI Pharma (NASDAQ:CASI)
CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development. Its ENMD-2076 is an orally active, Aurora A/angiogenic kinase inhibitor with a kinase selectivity profile and multiple mechanisms of action. Its Marqibo is a sphingomyelin/cholesterol liposome-encapsulated, formulation of vincristine sulfate. Its ZEVALIN (ibritumomab tiuxetan) injection for intravenous use is a CD20-directed radiotherapeutic antibody. Its EVOMELA is an intravenous formulation of melphalan being investigated by Spectrum in the multiple myeloma transplant setting. Its pipeline also includes 2ME2 (2-methoxyestradial).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.